TOP2A and small cell lung carcinoma: (Fig 9B) Methotrexate, Oxaliplatin, Carboplatin, Teniposide, Sunitinib, Cyclosporine, Aurofusarin, Dasatinib, Daunorubicin, Dronabinol, Etoposide, Fluorouracil, and Irinotecan might be viewed as targeted drugs for the treatment of SCLC patients with high expression of TOP2A.